Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis WorseningVlad Ratziu, Juan F. Gallegos‐Orozco, Velimir A. Luketic et al.|Gastroenterology|2016Cited by 1k
Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019Joong Sik Eom, Oana Săndulescu, Liliana Preoțescu et al.|Open Forum Infectious Diseases|2022Cited by 42
60 SILEN-C1: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTIONMark Sulkowski, Gerhard Steinmann, E. Ceasu et al.|Journal of Hepatology|2011Cited by 39
66 SILEN-C2: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO P/RMark Sulkowski, Gerhard Steinmann, Marc Bourlière et al.|Journal of Hepatology|2011Cited by 30